Serum CA 19-9 as a Marker for Pancreatic Cancer Treatment

Strategic Insights -

A recent study published in the Annals of Surgical Oncology has shed light on the effectiveness of serum carbohydrate antigen (CA) 19-9 as a marker for pancreatic cancer treatment. Researchers from the United States evaluated the role of CA 19-9 in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. The study analyzed 174 patients, of whom 119 (68%) completed all therapy, including pancreaticoduodenectomy (PD), and found that CA 19-9 levels were predictive of therapeutic response and survival.

Key Takeaways:

  • The study involved 174 patients with radiographically resectable adenocarcinoma of the head/uncinate process treated with neoadjuvant chemoradiation.
  • 119 patients (68%) completed all therapy, including pancreaticoduodenectomy (PD), indicating a significant level of treatment compliance.
  • CA 19-9 levels were evaluated in patients with a normal bilirubin level, which is essential for accurate testing.
  • The researchers concluded that CA 19-9 is not a reliable marker for predicting resectability or survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.
  • Decision-making for patients with resectable pancreatic cancer should remain based on clinical assessment and radiographic staging.

Statistics:

  • 174 patients were enrolled in the study, representing a significant sample size for pancreatic cancer research.
  • 119 patients (68%) completed all therapy, including PD, which is a crucial factor in determining treatment efficacy.
  • CA 19-9 levels were evaluated in patients with a normal bilirubin level, indicating a crucial aspect of accurate testing.
  • The study suggests that CA 19-9 is not a reliable marker for predicting resectability or survival, highlighting the complexity of pancreatic cancer treatment.

Sources:

  • Katz, M.H., et al. (2010). Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Annals of Surgical Oncology, 17(7), 1794-801.
  • Biotech Week editors. (2010). Serum CA 19-9 as a Marker for Pancreatic Cancer Treatment. Biotech Week via NewsRx.com.